Sigyn Therapeutics, Inc. ("Sigyn" or the "Company") (OTCQB: SIGY), a developer of dialysis-like therapies to address cardiovascular disease and cancer, today released a note authored by inventor and ...
A nonselective extracorporeal blood purification (EBP) device connected to the cardiopulmonary bypass circuit during surgery reduced the risk of cardiac surgery-associated acute kidney injury (CSA-AKI ...
Please provide your email address to receive an email when new articles are posted on . The cardiac surgery-linked AKI rate was 28.4% among patients on extracorporeal blood purification. The rate was ...
About The Study: The use of a nonselective extracorporeal blood purification device connected to the cardiopulmonary bypass circuit in a nonemergent population of patients undergoing cardiac surgery ...
MARTINEZ, Calif.--(BUSINESS WIRE)--Critically ill patients treated with ExThera Medical’s Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100) within 60 hours of ICU admission experienced a ...
Acute sepsis profoundly changes how intravenous fluids behave within the body. Using a sheep model, researchers investigated ...
Santersus AG Announces Advancement of NucleoCapture into Pivotal Clinical Development strengthened by Strategic Collaboration with Terumo Zurich, Switzerland, 1st Dec 2025 – Santersus AG today ...
SAN DIEGO, CA, Sept. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTCQB: SIGY), a development-stage company focused on the creation of therapeutic solutions that address ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback